SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity’s UltraMIST and Exclusive Partnership Rights for Wound Care Biologic Products - Seite 2

SANUWAVE will conduct an investor teleconference at 9:00 a.m. EDT today.  Investors can access this conference via the following:

·       Live webcast at https://www.webcaster4.com/Webcast/Page/2249/35268

·       Live telephone:

              Call 844-602-0380 within the U.S. or [phone] outside the U.S. Please join the call at least 10 minutes before the start time.

·       Webcast replay:

              Go to https://www.webcaster4.com/Webcast/Page/2249/35268 . The webcast replay will be available until Thursday, September 10, 2020.

·       Telephone replay:

Call 877-481-4010 within the U.S. or [phone] (for both U.S. and outside U.S., the access code is 35268).  The telephone replay will be available until Wednesday, June 17, 2020.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com) is a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron and orthoPACE devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shockwave technology for non-medical uses, including energy, water, food and industrial markets.